Friday, October 30, 2026
26.6 C
Bengaluru

MedicinMan Indian Pharma Digital Adoption Survey

Smaller Indian pharma companies bore the strongest impact from COVID-19 pandemic - MedicinMan Indian Pharma Digital Adoption Survey

Smaller Indian pharma companies with less than a 100 MSRs and less than Rs.100 Cr. turnover were the most highly impacted from the COVID-19 pandemic in the last 12 months. That can be explained by the fact that contact with local doctors was their only channel of communication and it was shut as India was one of the first countries to go into a lockdown in March 2020.

As a whole, Indian domestic companies saw greater impact on their revenues compared to MNCs. The biggest reasons for revenue impact turn out to be lack of customer engagement and supply chain issues.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

China’s Biopharma Strategy: A Warning and Opportunity for India

China is playing a long game in biopharma. And...

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy,...

Topics

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...
spot_img

Related Articles

spot_imgspot_img